LIVZON PHARMAC (Germany) Top Insiders

LP6 Stock  EUR 3.40  0.18  5.59%   
Examination of LIVZON PHARMAC's management performance can provide insight into the company performance.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LIVZON PHARMAC GRP. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Symbol  LP6
Name  LIVZON PHARMAC GRP
TypeStock
Country  
 Germany
Exchange  F

Information on LIVZON PHARMAC GRP Leadership is currently not available.

If you believe this information is not accurate please let us know and we will check it out. Check all delisted instruments across multiple markets.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

LIVZON PHARMAC Management Team Effectiveness

The company has return on total asset (ROA) of 0.0514 % which means that it generated a profit of $0.0514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1333 %, meaning that it generated $0.1333 on every $100 dollars invested by stockholders. LIVZON PHARMAC's management efficiency ratios could be used to measure how well LIVZON PHARMAC manages its routine affairs as well as how well it operates its assets and liabilities.

LIVZON PHARMAC Workforce Comparison

LIVZON PHARMAC GRP is rated fourth overall in number of employees category among its peers. The total workforce of Drug Manufacturers-Specialty & Generic industry is now estimated at about 122,623. LIVZON PHARMAC holds roughly 8,580 in number of employees claiming about 7% of equities under Drug Manufacturers-Specialty & Generic industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.

LIVZON PHARMAC GRP Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. LIVZON PHARMAC GRP Price Series Summation is a cross summation of LIVZON PHARMAC price series and its benchmark/peer.

About LIVZON PHARMAC Management Performance

The success or failure of an entity such as LIVZON PHARMAC GRP often depends on how effective the management is. LIVZON PHARMAC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LIVZON management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LIVZON management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the Peoples Republic of China. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China. Livzon Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Germany and traded on Frankfurt Stock Exchange. It employs 6963 people.

Complementary Tools for LIVZON Stock analysis

When running LIVZON PHARMAC's price analysis, check to measure LIVZON PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LIVZON PHARMAC is operating at the current time. Most of LIVZON PHARMAC's value examination focuses on studying past and present price action to predict the probability of LIVZON PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LIVZON PHARMAC's price. Additionally, you may evaluate how the addition of LIVZON PHARMAC to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing